Summary & Overview
HCPCS J2792: Rho(D) Immune Globulin, Intravenous, 100 IU
HCPCS Level II code J2792 represents an intravenous formulation of Rho(D) immune globulin, human, solvent detergent treated, in 100 IU units. This biologic product is used to provide passive immunization against Rho(D) antigen and is administered intravenously in outpatient infusion settings. Nationally, accurate coding for immune globulin therapies matters for clinical continuity, claims processing, and monitoring utilization of plasma-derived products.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines coverage and billing considerations across major national payers and presents clinical context for Rho(D) immune globulin use in prevention of Rho(D)-related alloimmunization.
Readers will find concise benchmarks and coding guidance relevant to billing and documentation: common sites of service for intravenous immune globulin, the service type, and payer landscape. The summary includes policy and coding updates where available, utilization considerations for infusion settings, and points for documentation to support medical necessity. Data not available in the input for payer-specific reimbursement rates, associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J2792 describes an intravenous injection of Rho(D) immune globulin, human, solvent detergent treated, measured in 100 IU units. This product is an immune globulin preparation derived from pooled human plasma and is used to provide passive immunization against Rho(D) antigen.
Service Type: Intravenous immune globulin administration
Typical Site of Service: Hospital outpatient infusion center or clinic; ambulatory infusion center; or other outpatient settings where intravenous biologic therapies are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an Rh-negative pregnant woman who has been exposed to Rh-positive fetal red blood cells during pregnancy or at delivery, or an Rh-negative individual who requires passive immunization after sensitizing events (for example, abdominal trauma, invasive prenatal procedures, or transfusion of Rh-positive blood). The medication J2792 (intravenous Rho(D) immune globulin, solvent/detergent-treated) is administered in an outpatient infusion center, hospital inpatient unit, labor and delivery unit, or emergency department depending on clinical circumstances.
A typical workflow: the patient is evaluated by the obstetric or emergency care team, relevant laboratory testing (blood type and antibody screen, Kleihauer-Betke or fetal rosette test as indicated) is ordered, informed consent is obtained, and the infusion order for J2792 is placed. Pharmacy verifies dose based on exposure and international units required, prepares the solvent/detergent-treated human Rho(D) immune globulin, and the infusion nurse administers IV therapy per protocol with vital sign monitoring. Documentation includes indication, lot number, dose in international units, route (intravenous), date/time, and any adverse reactions. Follow-up orders (repeat antibody screen, postpartum dosing if applicable) are placed according to clinical guidelines.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|